NYSE:ZYME - Zymeworks Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.11
  • Forecasted Upside: 49.62 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$34.16
▼ -2.45 (-6.69%)
1 month | 3 months | 12 months
Get New Zymeworks Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZYME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZYME

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$51.11
▲ +49.62% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is $51.11, with a high forecast of $74.00 and a low forecast of $38.00. The average price target represents a 49.62% upside from the last price of $34.16.
Buy
The current consensus among 10 polled investment analysts is to buy stock in Zymeworks. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2019
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/9/2019
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/8/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/6/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/4/2020
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/3/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/1/2021
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/3/2021Raymond JamesSet Price TargetStrong-Buy$74.00Medium
i
3/3/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$50.00 ➝ $41.00High
i
Rating by A. Berens at SVB Leerink LLC
2/25/2021Raymond JamesSet Price TargetStrong-Buy$74.00High
i
2/25/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$50.00 ➝ $41.00High
i
Rating by A. Berens at SVB Leerink LLC
2/8/2021HC WainwrightReiterated RatingBuy$57.00Low
i
Rating by R. Burns at HC Wainwright
2/3/2021Raymond JamesSet Price TargetStrong-Buy$74.00Low
i
1/29/2021CitigroupUpgradeNeutral ➝ BuyLow
i
1/28/2021Wells Fargo & CompanyLower Price Target$71.00 ➝ $56.00Low
i
1/28/2021Raymond JamesSet Price TargetStrong-Buy$74.00Low
i
1/28/2021SVB LeerinkLower Price TargetOutperform$66.00 ➝ $50.00Low
i
Rating by A. Berens at SVB Leerink LLC
1/28/2021BarclaysLower Price TargetEqual Weight$47.00 ➝ $38.00High
i
1/25/2021CitigroupDowngradeBuy ➝ Neutral$50.00 ➝ $53.00High
i
1/19/2021Raymond JamesBoost Price TargetStrong-Buy$60.00 ➝ $74.00Medium
i
1/12/2021Raymond JamesSet Price TargetStrong-Buy$60.00High
i
1/12/2021Wells Fargo & CompanyBoost Price TargetOverweight$58.00 ➝ $71.00High
i
1/12/2021SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $66.00High
i
Rating by A. Berens at SVB Leerink LLC
12/2/2020Raymond JamesSet Price TargetStrong-Buy$60.00Low
i
11/17/2020Raymond JamesSet Price TargetStrong-Buy$60.00High
i
11/4/2020Raymond JamesSet Price TargetStrong-Buy$60.00High
i
10/26/2020Raymond JamesSet Price TargetStrong-Buy$60.00Low
i
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
i
8/6/2020Raymond JamesSet Price TargetStrong-Buy$60.00Medium
i
8/6/2020SVB LeerinkInitiated CoverageOutperform$45.00Medium
i
Rating by A. Berens at SVB Leerink LLC
7/16/2020Raymond JamesSet Price TargetStrong-Buy$60.00Low
i
Rating by David Novak at Raymond James
7/14/2020GuggenheimLower Price Target$54.00 ➝ $48.00Low
i
7/13/2020Canaccord GenuityBoost Price TargetBuy$25.00 ➝ $42.00High
i
7/9/2020Raymond JamesSet Price TargetStrong-Buy$60.00Medium
i
Rating by David Novak at Raymond James
7/9/2020HC WainwrightLower Price TargetBuy$60.00 ➝ $54.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/14/2020Bloom BurtonReiterated RatingBuyLow
i
Rating by D. Martin at Bloom Burton
6/3/2020Raymond JamesSet Price TargetStrong-Buy$60.00Low
i
Rating by David Novak at Raymond James
6/2/2020CitigroupBoost Price TargetBuy$49.00 ➝ $50.00High
i
5/8/2020Paradigm CapitalReiterated RatingBuy$51.00Medium
i
Rating by Corey Hammill at Paradigm Capital
5/8/2020Raymond JamesSet Price TargetStrong-Buy$60.00High
i
Rating by David Novak at Raymond James
5/8/2020HC WainwrightReiterated RatingBuy$60.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/2/2020Raymond JamesSet Price TargetStrong-Buy$60.00Low
i
Rating by David Novak at Raymond James
3/3/2020HC WainwrightReiterated RatingBuy$65.00 ➝ $60.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/20/2020HC WainwrightReiterated RatingBuy$65.00Low
i
Rating by D. Chattopadhyay at HC Wainwright
2/3/2020Stifel NicolausBoost Price TargetBuy$45.00 ➝ $70.00Medium
i
Rating by Stephen Willey at Stifel Nicolaus
1/15/2020Wells Fargo & CompanyReiterated RatingOverweight$48.00 ➝ $58.00Low
i
1/14/2020Raymond JamesReiterated RatingBuy$60.00Low
i
Rating by David Novak at Raymond James
1/10/2020Wolfe ResearchInitiated CoverageOutperform$61.00High
i
12/9/2019JPMorgan Chase & Co.Initiated CoverageNeutral$43.00High
i
11/27/2019GuggenheimInitiated CoverageBuy$48.00Low
i
Rating by Etzer Darout at Guggenheim
11/25/2019Raymond JamesBoost Price TargetStrong-Buy$40.00 ➝ $60.00Low
i
Rating by David Novak at Raymond James
11/25/2019HC WainwrightInitiated CoverageBuy$65.00High
i
Rating by D. Chattopadhyay at HC Wainwright
11/21/2019Stifel NicolausReiterated RatingBuyHigh
i
Rating by Stephen Willey at Stifel Nicolaus
11/19/2019GuggenheimInitiated CoverageBuy$48.00Medium
i
11/7/2019Raymond JamesSet Price TargetStrong-Buy$40.00High
i
Rating by David Novak at Raymond James
10/29/2019Raymond JamesSet Price TargetStrong-Buy$40.00Low
i
Rating by David Novak at Raymond James
10/17/2019Raymond JamesReiterated RatingStrong-Buy$40.00Low
i
Rating by David Novak at Raymond James
9/30/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$36.00 ➝ $40.00High
i
9/27/2019Raymond JamesSet Price TargetOutperform$36.00High
i
8/30/2019Stifel NicolausInitiated CoverageBuy$45.00High
i
8/27/2019CitigroupBoost Price TargetBuy$22.00 ➝ $49.00Medium
i
8/7/2019Raymond JamesSet Price TargetOutperform$36.00Low
i
8/5/2019BarclaysBoost Price TargetEqual Weight$15.00 ➝ $23.00Medium
i
7/31/2019Raymond JamesSet Price TargetOutperform$36.00Medium
i
7/18/2019Raymond JamesReiterated RatingOutperform$36.00Low
i
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$34.00Medium
i
5/30/2019Raymond JamesReiterated RatingOutperform$36.00High
i
5/15/2019Raymond JamesSet Price TargetOutperform$36.00Low
i
5/3/2019Canaccord GenuitySet Price TargetBuy$23.00Low
i
Rating by Arlinda Lee at Canaccord Genuity
5/3/2019Raymond JamesSet Price TargetOutperform$36.00Low
i
4/26/2019Raymond JamesBoost Price TargetOutperform$29.00 ➝ $36.00Low
i
4/22/2019Wells Fargo & CompanyBoost Price TargetOutperform$37.00 ➝ $42.00Low
i
3/14/2019Raymond JamesSet Price TargetOutperform$29.00Medium
i
3/8/2019Raymond JamesReiterated RatingOutperform$29.00Low
i
12/10/2018Raymond JamesSet Price TargetOutperform$29.00Medium
i
Rating by David Novak at Raymond James
11/28/2018Raymond JamesBoost Price TargetOutperform$27.00 ➝ $29.00High
i
Rating by David Novak at Raymond James
11/28/2018Canaccord GenuitySet Price TargetBuy$21.00High
i
Rating by Arlinda Lee at Canaccord Genuity
10/15/2018Raymond JamesSet Price TargetOutperform$27.00Low
i
Rating by David Novak at Raymond James
9/5/2018Raymond JamesSet Price TargetBuy$27.00Low
i
Rating by David Novak at Raymond James
9/5/2018Canaccord GenuitySet Price TargetBuy$21.00Low
i
Rating by Arlinda Lee at Canaccord Genuity
8/15/2018Raymond JamesReiterated RatingBuy$27.00Low
i
8/2/2018CitigroupUpgradeNeutral ➝ Buy$19.00High
i
6/21/2018CitigroupLower Price TargetNeutral ➝ Neutral$20.00 ➝ $19.00Low
i
6/6/2018CitigroupDowngradeBuy ➝ NeutralHigh
i
6/5/2018Raymond JamesBoost Price TargetOutperform ➝ Outperform$22.00 ➝ $27.00Medium
i
6/4/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$20.00 ➝ $37.00Medium
i
5/18/2018Raymond JamesBoost Price TargetOutperform$18.00 ➝ $22.00Low
i
5/16/2018Canaccord GenuityBoost Price TargetBuy$18.00 ➝ $21.00Medium
i
5/14/2018LADENBURG THALM/SH SHInitiated CoverageBuy$25.00Low
i
5/11/2018BarclaysUpgradeUnderweight ➝ Equal Weight$8.00 ➝ $15.00High
i
3/19/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$18.00Low
i
9/30/2017CormarkReiterated RatingBuyMedium
i
9/7/2017BarclaysReiterated RatingOverweight ➝ Underweight$8.00High
i
5/23/2017CitigroupInitiated CoverageBuy ➝ Buy$18.00Low
i
5/23/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$20.00Low
i
5/23/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$18.00Low
i
5/23/2017BarclaysInitiated CoverageOverweight ➝ Overweight$20.00Low
i
(Data available from 3/3/2016 forward)
Zymeworks logo
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $34.16
$33.90
$37.02

50 Day Range

MA: $43.83
$33.82
$56.25

52 Week Range

Now: $34.16
$20.33
$59.03

Volume

321,012 shs

Average Volume

606,410 shs

Market Capitalization

$1.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Zymeworks?

The following Wall Street research analysts have issued reports on Zymeworks in the last year: Barclays PLC, Bloom Burton, Canaccord Genuity, Citigroup Inc., Guggenheim, HC Wainwright, JPMorgan Chase & Co., Paradigm Capital, Raymond James, SVB Leerink LLC, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for ZYME.

What is the current price target for Zymeworks?

9 Wall Street analysts have set twelve-month price targets for Zymeworks in the last year. Their average twelve-month price target is $51.11, suggesting a possible upside of 39.6%. Raymond James has the highest price target set, predicting ZYME will reach $74.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $38.00 for Zymeworks in the next year.
View the latest price targets for ZYME.

What is the current consensus analyst rating for Zymeworks?

Zymeworks currently has 3 hold ratings, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZYME will outperform the market and that investors should add to their positions of Zymeworks.
View the latest ratings for ZYME.

What other companies compete with Zymeworks?

How do I contact Zymeworks' investor relations team?

Zymeworks' physical mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company's listed phone number is 604-678-1388 and its investor relations email address is [email protected] The official website for Zymeworks is www.zymeworks.com.